FGFR1 and cancer: However, peptibodyC19 contains, in addition, two cysteine residuesin the targeting peptide sequence, which covalently modified withthe drug could result in decreased affinity for the FGFR1 and lessefficient delivery of the cytotoxic payload to cancer cells.